Overview
Draig Therapeutics emerged in June 2025 with $140 million in combined seed and Series A funding, making it one of the largest launches in CNS therapeutics. The company is developing gene therapies that target previously undruggable neurological conditions.
Scientific Approach
Draig's platform uses engineered adeno-associated virus (AAV) vectors with enhanced CNS tropism — meaning they can cross the blood-brain barrier more efficiently and deliver therapeutic genes directly to neural tissue. This addresses one of the biggest historical challenges in CNS drug development: getting medicines into the brain.
Pipeline
While specific indications haven't been fully disclosed, the company has signaled interest in rare neurogenetic disorders where single-gene mutations cause devastating neurological symptoms — conditions where gene therapy could potentially provide one-time curative treatment rather than lifelong symptom management.
Industry Impact
The size of this launch signals strong investor conviction in CNS gene therapy despite the sector's historically high failure rates. Success here could open the door for gene therapy approaches to more common neurological conditions like Parkinson's and ALS.
